Overview

50 Studies Every Endocrinologist Should Know assembles landmark, evidence-based studies in classic endocrinology to guide readers towards solving thorny endocrine problems. Featuring a diverse range of study types--including RCTs, multicenter trials, observational studies, and meta-analyses--this volume addresses the core issues faced by endocrinologists in clinical practice. Each chapter provides a concise summary of key studies, highlighting results, limitations, and practical implications. The chapters conclude with a list of major take-home points, which collectively form a foundation of Endocrine Principles that can be applied to real-word patient problems. As with all books in the ""50 Studies"" series, each study was selected using an objective selection criterion that included citations per year, high levels of evidence, clinical studies and trials, and a 3-stage Delphi review by international experts in the field. It is an indispensable reference for fellows, physicians, nurse practitioners, and any primary providers with an interest in endocrinology, as well as those taking both the endocrinology board exam and the Endocrinology, Diabetes, & Metabolism certification exam.

Full Product Details

Author:   John Interlandi (Medical Director, Medical Director, Botts Diabetes Endocrinology Clinic, New Horizon Clinic)
Publisher:   Oxford University Press Inc
Imprint:   Oxford University Press Inc
Dimensions:   Width: 15.70cm , Height: 2.50cm , Length: 22.90cm
Weight:   0.612kg
ISBN:  

9780197684702

ISBN 10:   019768470
Pages:   448
Publication Date:   17 January 2026
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Forthcoming
Availability:   To order  

Table of Contents

SECTION 1: Conditions caused by Thyroid Damage Chapter 1: Screening for Thyroid Disease in Early Pregnancy and in Pre-Pregnancy Chapter 2: Subclinical Hypothyroidism Chapter 3: Management of Thyroxine in Non-Ablated Patients with Hypothyroidism Chapter 4: Optimal Thyroid Replacement for the Athyreotic Patient SECTION 2: Conditions Causing Thyroid Overactivity Chapter 5: Antithyroid Drugs vs. Ablation in Community Treatment for Graves>' Disease Chapter 6: Optimum Use of Antithyroid Drugs in Hyperthyroidism Chapter 7: Risks of I-131 Treatment of Hyperthyroidism Chapter 8: Hyperthyroidism caused by Amiodarone (AIT) SECTION 3: Focal and Structural Thyroid Disease Chapter 9: Selection of Thyroid Nodules to be Biopsied Chapter 10: Selection of Patients over 45 for Thyroid Biopsy Chapter 11: Molecular Genomic Testing (MGT) for Indeterminate Thyroid Nodules Chapter 12: Complication Rate(s) from Thyroidectomy Chapter 13: Ablation Techniques for Benign or Hot Nodules Chapter 14: Microscopic Papillary Thyroid Carcinoma (mPTC) and Active Surveillance (AS) Chapter 15: Optimal Work-up and Surgery for a small, non-metastatic DTCA Chapter 16: I-131 Treatment for DTCA SECTION 4: Parathyroid Diseases Chapter 17: Active Surveillance and/or Medical Therapy for Hyperparathyroidism in Older Patients Chapter 18: Preoperative Localization of Sporadic Primary Hyperparathyroidism Chapter 19: Quality of Life after Surgery for Mild/Moderate Sporadic Primary Hyperparathyroidism Chapter 20: Secondary Hyperparathyroidism, Idiopathic Hypercalciuria, and Bone Density Chapter 21: Recurrent and/or Persistent Primary Hyperparathyroidism SECTION 5: Metabolic Bone Disease Chapter 22: Calcium and Vitamin D Effects on Bone Mass Chapter 23: Fracture Prevention in Patients with Low Bone Mass Chapter 24: Pretreatment Evaluation for Osteoporosis Chapter 25: Evaluation of Fracture Risk in Osteoporosis Chapter 26: Osteoporosis and Hip Fracture Prevention Chapter 27: Alendronate and Fracture Risk Reduction Chapter 28: Hip Fracture in the Elderly with Very Low Bone Density Chapter 29: Anabolic Agent(s) for Osteoporosis Chapter 30: Glucocorticoid Osteoporosis Chapter 31: Osteoporosis in Men SECTION 6: Adrenal Conditions Chapter 32: The Importance of Recognizing Hyperaldosteronism Chapter 33: Effectiveness of Treatment of Hyperaldosteronism Chapter 34: Screening for Adrenal Insufficiency Chapter 35: Adrenal Incidentalomas Chapter 36: Opioid-Induced Endocrine Deficiencies Chapter 37: Adrenal Insufficiency from Corticosteroid Treatment Chapter 38: Optimal Testing for ACTH-Dependent Hypercortisolism SECTION 7: Pituitary Tumors / Hypercortisolism Chapter 39: Duration of Medical Treatment of Intrasellar Prolactinomas Chapter 40: Acromegaly Treatment-Surgery, Medication, or What? Chapter 41: Primary Treatment of Pituitary Hypercortisolism Chapter 42: Treatment of Recurrent or Persistent Hypercortisolism SECTION 8: Conditions Caused by Testosterone Deficiency Chapter 43: Risks of Testosterone Treatment in Older Men Chapter 44: Male Obesity Secondary Hypogonadism (MOSH) SECTION 9: Conditions Related to Estrogen Deficiency Chapter 45: Estrogen Treatment and Cardiovascular Health Chapter 46: Estrogen Treatment and Skeletal Health Chapter 47: Estrogen + Progestin vs. Estrogen Alone, and Neoplasia SECTION 10: Polycystic Ovary Syndrome Chapter 48: Optimal Differential Diagnosis of PCOS Chapter 49: Optimal Treatment of Hirsutism in PCOS Chapter 50: Treatment of Subfertility in PCOS

Reviews

Author Information

John Interlandi, MD, is a distinguished specialist in Endocrinology, Diabetes & Metabolism, and Internal Medicine. He is a graduate of the Vanderbilt University School of Medicine and completed his Internal Medicine Residency at the Medical College of Wisconsin in Milwaukee. He further honed his expertise through an Endocrine Fellowship at Vanderbilt and Nashville VA Hospitals. Dr. Interlandi has served in various academic roles, including Assistant Clinical Professor of Medicine and Associate Clinical Professor of Medicine at Vanderbilt University. His professional journey also includes significant contributions to medical research and clinical trials. He directed the Hepatic Activation Program at Donelson Hospital from 1992 to 1993 and led the Implantable Insulin Pump Project at the same hospital from 1988 to 1994. Additionally, he was involved in the Glyburide Multicenter Trial with Hoechst Pharmaceuticals and conducted Thyroid Biopsy Molecular Analysis Research at Summit Hospital. Dr. Interlandi has shared his knowledge through invited lectures on Thyroid Ultrasound at the AACE Course in Nashville. He also served on the Eli Global Advisory Board Currently, he works as a Medical Director practicing in Tennessee.

Tab Content 6

Author Website:  

Countries Available

All regions